Literature DB >> 10593336

Preferential loss of CXCR-2 receptor expression and function in patients who have undergone trauma.

G A Quaid1, C Cave, C Robinson, M A Williams, J S Solomkin.   

Abstract

BACKGROUND: In response to traumatic injury or infection, human neutrophils are directed to the site of injury or infection by CXC chemokines that signal via 2 receptors, CXCR-1 and CXCR-2. In vitro studies have shown preferential loss of CXCR-2 expression and function after exposure to interleukin 8, N-formyl-methionyl-leucyl-phenylalanine (fMLP), C5a, and tumor necrosis factor alpha. HYPOTHESIS: CXCR-2 expression and function are preferentially down-regulated in severely injured patients.
METHODS: We studied 20 patients within 24 hours of admission to the hospital. Patients with head injuries were excluded. Injury Severity Scores (range, 1-50; mean, 35) were calculated for each patient. To determine expression of CXCR-1 and CXCR-2, flow cytometry was used. Intracellular calcium mobilization and neutrophil migration to 10 nmol of interleukin 8, growth-related oncogene alpha, and fMLP was measured to determine receptor function.
RESULTS: Compared with CXCR-1, there is a greater loss of CXCR-2 receptor expression in the severely injured group (P = .01). Neutrophils from patients with Injury Severity Scores greater than 16 did not mobilize calcium in response to growth-related oncogene alpha. However, there was no loss of calcium mobilization to interleukin 8 or fMLP. Chemotaxis to various stimulants is decreased in all injury groups.
CONCLUSIONS: CXCR-2 expression and function are preferentially down-regulated in severely injured patients. Our data suggest that there are multiple mechanisms, in addition to receptor down-regulation, that play a role in the loss of migration and calcium flux in human neutrophils after injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593336     DOI: 10.1001/archsurg.134.12.1367

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  8 in total

1.  Targeting ADAM17 in leukocytes increases neutrophil recruitment and reduces bacterial spread during polymicrobial sepsis.

Authors:  Hemant K Mishra; Timothy J Johnson; Davis M Seelig; Bruce Walcheck
Journal:  J Leukoc Biol       Date:  2016-04-08       Impact factor: 4.962

2.  Chemokine CXCL1-Mediated Neutrophil Trafficking in the Lung: Role of CXCR2 Activation.

Authors:  Kirti V Sawant; Renling Xu; Robert Cox; Hal Hawkins; Elena Sbrana; Deepthi Kolli; Roberto P Garofalo; Krishna Rajarathnam
Journal:  J Innate Immun       Date:  2015-07-01       Impact factor: 7.349

3.  Regulation of CXCR2 expression and function by a disintegrin and metalloprotease-17 (ADAM17).

Authors:  Hemant K Mishra; Chunmei Long; Nooshin S Bahaie; Bruce Walcheck
Journal:  J Leukoc Biol       Date:  2014-11-20       Impact factor: 4.962

4.  Rho-kinase signalling regulates trypsinogen activation and tissue damage in severe acute pancreatitis.

Authors:  D Awla; H Hartman; A Abdulla; S Zhang; M Rahman; S Regnér; H Thorlacius
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

5.  Mincle activation enhances neutrophil migration and resistance to polymicrobial septic peritonitis.

Authors:  Wook-Bin Lee; Ji-Jing Yan; Ji-Seon Kang; Quanri Zhang; Won Young Choi; Lark Kyun Kim; Young-Joon Kim
Journal:  Sci Rep       Date:  2017-01-23       Impact factor: 4.379

6.  Neutrophil kinetics and function after major trauma: A systematic review.

Authors:  Liam Db Finlay; Andrew Conway Morris; Adam M Deane; Alexander Jt Wood
Journal:  World J Crit Care Med       Date:  2021-09-09

Review 7.  The role of neutrophils in immune dysfunction during severe inflammation.

Authors:  Pieter H C Leliefeld; Catharina M Wessels; Luke P H Leenen; Leo Koenderman; Janesh Pillay
Journal:  Crit Care       Date:  2016-03-23       Impact factor: 9.097

Review 8.  Update on Neutrophil Function in Severe Inflammation.

Authors:  Esmaeil Mortaz; Shamila D Alipoor; Ian M Adcock; Sharon Mumby; Leo Koenderman
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.